Submit Content Become a member

Nutritional Growth Solutions (ASX:NGS), a global nutrition company that creates scientifically formulated and clinically studied supplements to support growth development in children, has launched its first nutrition bar – the first of several planned expansions to its product range.

The new Healthy Height® nutrition bar is formulated with the same profile as NGS’ Healthy Height® patented shake range that is clinically proven to increase growth development in children aged between 3 and 9 years old by 13.8% – 34% in their annual growth. 

The Healthy Height® nutrition bar is available exclusively online at www.healthy-height.com in North America, with additional markets to follow.

Liron Fendell, CEO and Managing Director of NGS said:

“We are very excited to be able to offer our clinically proven formulation through the new nutrition bar product. The snack bar category was worth approximately US$20 billion in 2018 and is growing at a 6.6% compound annual growth rate. New children bar launches tracked by Innova Market Insights in the US show a compound annual growth rate of +11.3% (CAGR, 2016-2020).

 “There is increasing consumer preference for bars with less sugar and which provide high fibre content, protein, and other nutritional value. The market for clinically proven nutrition products for children is also growing due to increasing education about preventative health measures, paediatric nutrition and its effect on child development and growth. 

“In addition, we see significant opportunity to provide a clinically proven Healthy Height® nutrition bar product to those using human growth hormones, which is a US$3.7 billion market last year that is forecast to grow to $8.5 billion by 2027.”

“Our patented formula was developed after more than 20 years of research into the link between nutrition and growth in children and have been clinically proven increase height. Being able to now offer this formula in shake and bar format increases access to our products, including for those that may not qualify for growth hormone therapy and be looking for alternative options.”

Rate article from Staff Writers: